HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Samrat Pharmachem Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 16 filings·Updated 19 Aug 2026
Showing 10 of 16 filings.
19 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended June 30, 2026.

Filed 14:25View Source
14 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Samrat Pharmachem reports unaudited standalone Q1 2026 results; board takes on record

Unaudited Standalone Q1 FY2026 results

  • Unaudited standalone Q1 FY2026 results approved: revenue 7,976.10; total income 8,074.92; PBT 158.53; PAT 87.60.

Governance actions

  • Audit Committee reviewed results; Board took on record at meeting.

Business profile

  • Single business segment: pharmaceutical chemicals.
Filed 20:14View Source
17 Jul 20262 filings
Company UpdateAppointment of Statutory Auditor/s

Appointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting

Filed 15:44View Source
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate confirms dematerialisation processing, listing of securities, and ownership update per timelines.

Dematerialisation status

  • Dematerialisation requests were processed and confirmed/rejected to the depositories.
  • Dematerialised securities have been listed on the stock exchanges where prior issues are listed.
  • Physical certificates were mutilated and cancelled; depository name substituted as registered owner within timelines.
Filed 14:58View Source
30 Jun 20261 filing
Board Meeting

Samrat Pharmachem Board to consider Un-Audited Ind-AS results for quarter ended June 30, 2026

Meeting Details

  • Board meeting on Aug 14, 2026 at 02:00 PM at 701/702, Business Square, Andheri (W), Mumbai 400058.

Key Agenda Items

  • Consider and take on record Un-Audited Ind-AS financial results for quarter ended 30 June 2026.

Other Notes

  • Intimate unaudited results to exchanges and issue press release after the meeting.
Filed 15:10View Source
4 Jun 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31, 2026.

Filed 13:25View Source
30 Mar 20261 filing
Company UpdateCredit Rating

Samrat Pharmachem Ltd-$ - 530125 - Announcement under Regulation 30 (LODR)-Credit Rating

Credit Rating Action

  • Crisil Limited upgraded bank facilities rating to Crisil BB/Stable and Crisil A4+
  • Previous rating was Crisil BB+/Negative and Crisil A4+

Rating Agency

  • Rating agency involved is Crisil Limited

Outlook

  • Outlook changed from Negative to Stable
Filed 14:39View Source
25 Mar 20262 filings
Insider Trading / SASTClosure of Trading Window

Closure of Trading Window from 01-04-2026 till 48 hours after the declaration of Audited Financial Results for the year ended 31/03/2026

Filed 14:58View Source
Board Meeting

Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Intimation for Audited Financial Results For The Financial Year Ended March 31, 2026

Meeting Details

  • Board meeting scheduled for May 30, 2026, at 2:00 PM
  • Meeting location: Corporate Office, 701/702 Business Square, Andheri West, Mumbai

Key Agenda Items

  • Consider and approve audited standalone financial results for FY ended March 31, 2026
  • Review audit reports of the statutory auditor for FY ended March 31, 2026
Filed 14:51View Source
12 Jan 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate u/r 74(5) for the quarter ended 31/12/2025

Filed 14:47View Source
Showing 10 of 16 filings